A new mouse study led by UCLA Health suggests that inflammation during pregnancy can trigger autism-like changes in offspring ...

Occult hepatitis B virus (OBI) infection presents a significant global health challenge, notoriously flying under the radar of standard viral screening while relentlessly driving the pathogenesis of ...

Older adults losing muscle strength now have a clearer molecular explanation for why regular physical activity slows that ...

The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing ...

Malignant melanoma is one of the most dangerous forms of cancer. Around half of melanomas and about 7% of all other cancers ...

Several types of cancer are triggered by mutations in a protein called BRAF. Researchers at the Paul Scherrer Institute PSI have resolved a previously unknown conformation adopted by this protein ...

Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical ...

Newly discovered protein conformation offers a potential target for cancer drugs. Villigen, 21.07.2026 — Several types of ...

Mast cell biology spans immunology, inflammation, and tissue homeostasis. Traditionally viewed as principal effectors of IgE-mediated allergic reactions, ...

First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal vascular development, bleeding, and arteriovenous malfo ...

Harbour BioMed and Kelun-Biotech have received approval from China’s NMPA for their IND application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.

BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara™ cellular wellness platform ahead of the August 1, 2026, commercial launch of XcellaraHeart™. The platform ...